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Targeting p53’s main negative regulator MDM2 is a promising strategy for treating cancers that retain wild-
type p53. Unfortunately, MDM2 inhibitors are largely ineffective against tumors overexpressingMDMX. In this
issue of Cancer Cell, Bernal et al. describe a ‘‘stapled’’ peptide that targets MDMX and suppresses the
growth of tumors resistant to MDM2 inhibitors.p53 tumor suppressor function is abro-
gated by mutations or deletions of the
TP53 locus in about 50% of all human
cancers. The remaining cancers often
employ alternative mechanisms to
subvert the activity of wild-type p53; for
example, amplification and overexpres-
sion of the p53 negative regulator MDM2
(reviewed in Marine and Lozano, 2010).
Ample evidence suggests that trans-
formed cells are more sensitive to p53
activation than their normal counterparts.
Accordingly, restoration of p53 activity in
mice causes tumor-specific cell death or
induction of senescence (Sharpless and
DePinho, 2007). Activation of the p53
response becomes, therefore, an attrac-
tive therapeutic goal.
Proof-of-concept experiments have
demonstrated the feasibility of restoring
p53 function in vitro by antagonizing
MDM2 as a therapeutic strategy for the
treatment of cancers retaining wild-type
p53. An elegant structural study had
revealed that a hydrophobic cleft on the
N-terminal portion of MDM2 engages
the amphipathic a-helix of p53 transacti-
vation domain (Kussie et al., 1996). This
observation led to the development of
potent and selective small molecule inhib-
itors of MDM2, which disrupt the p53-
MDM2 interaction by targeting the hydro-
phobic groove of MDM2. Nutlin-3, one of
these compounds, triggers p53-depen-
dent cell cycle arrest and even apoptosis
andexhibits antitumoractivities inanoste-
osarcomamurine xenograft model (Vassi-
lev et al., 2004). However, several caveats
have been raised by further basic cancer
research studies. Numerous studies in
mice indicate that Mdm2 loss leads topathologies due to induction of p53-
dependent cell death in normal cells,
including those that arequiescent and fully
differentiated (Marine and Lozano, 2010).
Hence, although the use of small molecule
inhibitors that have a limited half-life
may not have such dramatic effects as
genetic ablation of Mdm2, toxicity is one
potential concern of systemic exposure
to potent MDM2 inhibitors. Another major
limitation is that, although Nultin-3 kills
several cancer cell lines whether or not
MDM2 levels are elevated, other cancer
cells are largely immune to it. In particular,
tumor cells that overexpress the other
key negative regulator of p53, MDMX,
only poorly respond to Nutlin-3 (reviewed
in Wade and Wahl, 2009). Although the
N-terminal regions of MDM2 and MDMX
exhibit a high degree of similarity, Nutlin-
3’s affinity for MDMX is 40-fold lower
compared to MDM2 (reviewed in Marine
et al., 2007). This is likely to be due to
structural differences within the p53-
binding pockets and a region immediately
adjacent to it, the ‘‘flexible lid’’ (reviewed in
Wade and Wahl, 2009). This is a major
hurdle for anti-MDM2-based therapy,
since overexpression of MDMX as an
alternative route to p53 inactivation is
observed in a significant percentage
across a wide spectrum of tumors, i.e.,
4% in glioblastoma, 19% in breast carci-
nomas, and up to 65% in retinoblastoma
(reviewed in Marine et al., 2007). Conse-
quently, the development of compounds
that selectively target the p53-binding
domain of MDMX has become a pressing
therapeutic goal (reviewed in Wade and
Wahl, 2009). Supporting this view are
results frommousemodels which indicateCancer Cell 18, Nthat ablation of Mdmx is well tolerated in
most adult somatic tissues (reviewed in
Marine et al., 2007).
In this issue, Bernal and colleagues
(Bernal et al., 2010) show that a previously
engineered ‘‘stabilized alpha-helix’’ of p53
peptide, SAH-p53-8, preferentially targets
MDMX. This peptide was designed using
a chemical strategy known as ‘‘hydro-
carbon stapling’’ that installs an all-hydro-
carbon cross-link within peptides to
restore their a-helical structure. SAH-
p53-8 is one of the ‘‘stapled’’ peptides
that wasmodeled after the transactivation
domain of p53. Coimmunoprecipitation
(Co-IP) experiments indicate that this
peptide binds to both MDM2 and MDMX;
however, in vitro binding and competition
assays show a 25-fold greater binding
preference for MDMX.
Cell viability assays performed on
a series of cell lines expressing varying
ratios of the MDM2/MDMX/p53 proteins
indicated that in contrast to Nutlin-3, the
SAH-p53-8 peptide caused a dose-
dependent reactivation of p53 and inhibi-
tion of cell viability irrespective of MDMX
levels. Cells expressing high levels of
MDMX and p53 and low levels of MDM2,
which were most resistant to Nutlin-3
treatment, were in fact most sensitive to
SAH-p53-8. Importantly, SAH-p53-8 cyto-
toxicity was specifically dependent on the
presence of wild-type p53 and did not
significantly affect the viability of normal
human diploid fibroblasts. Co-IP and
proximity ligation in situ assay (or P-LISA)
show that, in contrast to Nutlin-3, SAH-
p53-8 efficiently blocked the formation
of p53-MDMX complexes. Importantly,
the pharmacological disruption of theovember 16, 2010 ª2010 Elsevier Inc. 399
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Figure 1. The p53/MDM2/MDMX Ratio Determines Cancer
Susceptibility to Pharmacologic Inhibition of MDM2 and/or MDMX
MDMX inhibitors, such as the ‘‘stapled’’ SAH-p53-8 peptide, trigger beneficial
p53 tumor-suppressor responses in cells expressing high levels of MDMX and
p53. If basal p53 levels are low, maximal rescue of p53 function is achieved by
combined exposure to an MDM2 inhibitor (MDM2i), which elevates p53 levels,
and an MDMX inhibitor (MDMXi), which blocks the formation of inhibitory
MDMX-p53 complexes.
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Previewsp53-MDMX complexes by the
peptide coincidedwith signifi-
cant transcriptional activation
of endogenous p53-target
genes and induction of p53-
dependent reduced tumor
cell viability.
Mouse genetic experiments
have highlighted nonoverlap-
ping and synergistic p53-
inhibitory activities of Mdm2
andMdmx throughout embry-
onicdevelopment (reviewed in
Marine et al., 2006).Moreover,
Chen and colleagues showed
that simultaneous disruption
of p53 binding to MDM2 and
MDMX using a peptide that
exhibits dual MDM2/MDMX
specificity results in efficient
p53 activation and apoptosis
of tumor cells overexpress-
ing MDM2 and MDMX (Hu
et al., 2007). Consistently,
SAH-p53-8 treatment sensi-
tized Nutlin-3-resistant cells
to Nutlin-3-mediated p53 up-
regulation and functional acti-
vation. This experiment was
conducted in cells in which
high levels of MDMX are ex-
pressed and the p53-MDMX
complexes are readily detect-
able by Co-IP experiments.
Nutlin-3 and SAH-p53-8
synergistically enhanced cy-
totoxicity, which was corre-
lated with a blockade of thep53-MDMX complex formation. Impor-
tantly, this synergism is observed only in
cells with relatively low basal levels of p53
and not in cells expressing very high p53
levels. In cells with low MDMX, treatment
with the peptide provides no added benefit
to Nutlin-3 treatment (Figure 1).
Finally, the authors assessed the
pharmacological potential of intravenous
administration of the peptide to suppress
tumor growth in a murine xenograft model.
In this experimental setting, SAH-p53-8
induced a p53-response in the tumor cells
andsignificantlysuppressed tumorgrowth.
The classical problems associated with
peptide-based therapy such as poor solu-
bility and cellular uptake, short-half life
in vivo due to protease-dependent degra-
dation seemed therefore to be overcome
by the chemical design of the ‘‘stapled’’
peptides, which confers protease resis-400 Cancer Cell 18, November 16, 2010 ª20tance and favors cellular uptake. Crucially,
no obvious toxicity of the peptide to normal
tissues was observed.
The work of Bernal et al. therefore
identifies one of the long-awaited, spe-
cific MDMX inhibitors. Notably, a high
throughput screening has recently been
used to identify a small molecule MDMX
antagonist (SJ-172550), which also binds
selectively toMDMXandkills cells express-
ing high levels of MDMX (Reed et al.,
2010). Importantly, SAH-p53-8 is the first
compound shown to efficiently induce a
p53 tumor-suppressive response in vivo.
The authors also provide a framework
for determining how to optimally apply
MDM2 and MDMX inhibitors to rescue
p53 tumor suppressor function in cancer.
The data predict that MDMX targeting will
be maximally effective when p53 levels
are either naturally high or pharmacologi-10 Elsevier Inc.cally elevated, for example,
as a result of Nutlin-3 treat-
ment, and when the p53-
MDMX complexes can be
readily detected (Figure 1).
The authors therefore suggest
that detection of such com-
plexes could in principle be
used as a valuable biomarker
for predicting therapeutic
efficacy.
The ability of SAH-p53-8,
either alone or in combination
with MDM2 inhibitors, to kill
cancers with elevated MDMX
levels widens very signifi-
cantly the spectrum of tumors
that are expected to be sensi-
tive to MDM2 and/or MDMX
blockade. This study there-
fore opens up new thera-
peutic opportunities and fur-
ther strengthens the concept
that pharmacological rescue
of p53 is a viable alternative
to current cytotoxic chemo-
therapy. The field now awaits
full validation of this concept
in clinical settings.
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